Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing
Abstract
Acute myeloid leukemia (AML) is a rare yet deadly cancer of the blood and bone marrow. Presently, induction chemotherapy with the DNA damaging drugs cytarabine (ARA-C) and idarubicin (IDA), known as 7 + 3, is the standard of care for most AML patients. However, 7 + 3 is a relatively ineffective therapy, particularly in older patients, and has serious therapy-related toxicities. Therefore, a diagnostic test to predict which patients will respond to 7 + 3 is a critical unmet medical need. We hypothesize that a threshold level of therapy-induced 7 + 3 drug-DNA adducts determines cytotoxicity and clinical response. We further hypothesize that in vitro exposure of AML cells to nontoxic diagnostic microdoses enables prediction of the ability of AML cells to achieve that threshold during treatment. Our test involves dosing cells with very low levels of 14C-labeled drug followed by DNA isolation and quantification of drug-DNA adducts via accelerator mass spectrometry. Here, we have shown proof of principle by correlating ARA-C- and DOX-DNA adduct levels with cellular IC50 values of paired sensitive and resistant cancer cell lines and AML cell lines. Moreover, we have completed a pilot retrospective trial of diagnostic microdosing for 10 viably cryopreserved primary AML samplesmore »
- Authors:
-
- Univ. of California, Sacramento, CA (United States). Davis School of Medicine, Division of Hematology and Oncology, Dept. of Internal Medicine
- Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
- Univ. of California, Sacramento, CA (United States). Davis School of Medicine, Division of Hematology and Oncology, Dept. of Internal Medicine; Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States); VA Northern California Health Care System, Mather, CA (United States)
- Univ. of California, Sacramento, CA (United States). Davis School of Medicine, Division of Hematology and Oncology, Dept. of Internal Medicine; Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States)
- Univ. of California, Sacramento, CA (United States). Davis School of Medicine, Division of Hematology and Oncology, Dept. of Internal Medicine; VA Northern California Health Care System, Mather, CA (United States)
- Publication Date:
- Research Org.:
- Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)
- Sponsoring Org.:
- USDOE National Nuclear Security Administration (NNSA)
- OSTI Identifier:
- 1513119
- Report Number(s):
- LLNL-JRNL-769867
Journal ID: ISSN 0893-228X; 961209
- Grant/Contract Number:
- AC52-07NA27344
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Chemical Research in Toxicology
- Additional Journal Information:
- Journal Volume: 31; Journal Issue: 10; Journal ID: ISSN 0893-228X
- Publisher:
- American Chemical Society (ACS)
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES
Citation Formats
Scharadin, Tiffany M., Malfatti, Michael A., Haack, Kurt, Turteltaub, Kenneth W., Pan, Chong-xian, Henderson, Paul T., and Jonas, Brian A. Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing. United States: N. p., 2018.
Web. doi:10.1021/acs.chemrestox.8b00107.
Scharadin, Tiffany M., Malfatti, Michael A., Haack, Kurt, Turteltaub, Kenneth W., Pan, Chong-xian, Henderson, Paul T., & Jonas, Brian A. Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing. United States. https://doi.org/10.1021/acs.chemrestox.8b00107
Scharadin, Tiffany M., Malfatti, Michael A., Haack, Kurt, Turteltaub, Kenneth W., Pan, Chong-xian, Henderson, Paul T., and Jonas, Brian A. Tue .
"Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing". United States. https://doi.org/10.1021/acs.chemrestox.8b00107. https://www.osti.gov/servlets/purl/1513119.
@article{osti_1513119,
title = {Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing},
author = {Scharadin, Tiffany M. and Malfatti, Michael A. and Haack, Kurt and Turteltaub, Kenneth W. and Pan, Chong-xian and Henderson, Paul T. and Jonas, Brian A.},
abstractNote = {Acute myeloid leukemia (AML) is a rare yet deadly cancer of the blood and bone marrow. Presently, induction chemotherapy with the DNA damaging drugs cytarabine (ARA-C) and idarubicin (IDA), known as 7 + 3, is the standard of care for most AML patients. However, 7 + 3 is a relatively ineffective therapy, particularly in older patients, and has serious therapy-related toxicities. Therefore, a diagnostic test to predict which patients will respond to 7 + 3 is a critical unmet medical need. We hypothesize that a threshold level of therapy-induced 7 + 3 drug-DNA adducts determines cytotoxicity and clinical response. We further hypothesize that in vitro exposure of AML cells to nontoxic diagnostic microdoses enables prediction of the ability of AML cells to achieve that threshold during treatment. Our test involves dosing cells with very low levels of 14C-labeled drug followed by DNA isolation and quantification of drug-DNA adducts via accelerator mass spectrometry. Here, we have shown proof of principle by correlating ARA-C- and DOX-DNA adduct levels with cellular IC50 values of paired sensitive and resistant cancer cell lines and AML cell lines. Moreover, we have completed a pilot retrospective trial of diagnostic microdosing for 10 viably cryopreserved primary AML samples and observed higher ARA-C- and DOX-DNA adducts in the 7 + 3 responders than nonresponders. In conclusion, these initial results suggest that diagnostic microdosing may be a feasible and useful test for predicting patient response to 7 + 3 induction chemotherapy, leading to improved outcomes for AML patients and reduced treatment-related morbidity and mortality.},
doi = {10.1021/acs.chemrestox.8b00107},
journal = {Chemical Research in Toxicology},
number = 10,
volume = 31,
place = {United States},
year = {Tue Aug 28 00:00:00 EDT 2018},
month = {Tue Aug 28 00:00:00 EDT 2018}
}
Web of Science
Figures / Tables:
Works referenced in this record:
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
journal, October 1996
- Weick, Jk; Kopecky, Kj; Appelbaum, Fr
- Blood, Vol. 88, Issue 8
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
journal, April 1999
- Gewirtz, DavidA
- Biochemical Pharmacology, Vol. 57, Issue 7
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
journal, December 2012
- Mrózek, Krzysztof; Marcucci, Guido; Nicolet, Deedra
- Journal of Clinical Oncology, Vol. 30, Issue 36
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
journal, January 2017
- Döhner, Hartmut; Estey, Elihu; Grimwade, David
- Blood, Vol. 129, Issue 4
Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations
journal, August 2008
- Coldwell, K. E.; Cutts, S. M.; Ognibene, T. J.
- Nucleic Acids Research, Vol. 36, Issue 16
A High-Throughput Method for the Conversion of CO 2 Obtained from Biochemical Samples to Graphite in Septa-Sealed Vials for Quantification of 14 C via Accelerator Mass Spectrometry
journal, May 2003
- Ognibene, Ted J.; Bench, Graham; Vogel, John S.
- Analytical Chemistry, Vol. 75, Issue 9
New Mechanistic and Functional Insights into DNA Topoisomerases
journal, June 2013
- Chen, Stefanie Hartman; Chan, Nei-Li; Hsieh, Tao-shih
- Annual Review of Biochemistry, Vol. 82, Issue 1
Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer
journal, January 2016
- Wang, Sisi; Zhang, Hongyong; Scharadin, Tiffany M.
- PLOS ONE, Vol. 11, Issue 1
Anthracycline Dose Intensification in Acute Myeloid Leukemia
journal, September 2009
- Fernandez, Hugo F.; Sun, Zhuoxin; Yao, Xiaopan
- New England Journal of Medicine, Vol. 361, Issue 13
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
journal, September 2013
- Pemovska, T.; Kontro, M.; Yadav, B.
- Cancer Discovery, Vol. 3, Issue 12
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]
journal, March 1996
- Bishop, Jf; Matthews, Jp; Young, Ga
- Blood, Vol. 87, Issue 5
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
journal, December 2010
- Krug, Utz; Röllig, Christoph; Koschmieder, Anja
- The Lancet, Vol. 376, Issue 9757
Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass
journal, November 2010
- Barpe, Deise Raquel; Rosa, Daniela Dornelles; Froehlich, Pedro Eduardo
- European Journal of Pharmaceutical Sciences, Vol. 41, Issue 3-4
A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer: Diagnostic microdosing approach
journal, May 2017
- Wang, Si-Si; Zimmermann, Maike; Zhang, Hongyong
- International Journal of Cancer, Vol. 141, Issue 3
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
journal, June 2014
- Yadav, Bhagwan; Pemovska, Tea; Szwajda, Agnieszka
- Scientific Reports, Vol. 4, Issue 1
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials
journal, January 2006
- Kern, Wolfgang; Estey, Elihu H.
- Cancer, Vol. 107, Issue 1
Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.
journal, May 1981
- Major, P. P.; Egan, E. M.; Beardsley, G. P.
- Proceedings of the National Academy of Sciences, Vol. 78, Issue 5
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
journal, December 2017
- Wei, Andrew H.; Tiong, Ing S.
- Blood, Vol. 130, Issue 23
Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer
journal, February 2013
- Cimino, George D.; Pan, Chong-xian; Henderson, Paul T.
- Bioanalysis, Vol. 5, Issue 3
The Power and Potential of Doxorubicin-DNA Adducts
journal, February 2005
- Cutts, Suzanne; Nudelman, Abraham; Rephaeli, Ada
- IUBMB Life (International Union of Biochemistry and Molecular Biology: Life), Vol. 57, Issue 2
Acute Myeloid Leukemia
journal, September 2015
- Döhner, Hartmut; Weisdorf, Daniel J.; Bloomfield, Clara D.
- New England Journal of Medicine, Vol. 373, Issue 12
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
journal, September 2009
- Löwenberg, Bob; Ossenkoppele, Gert J.; van Putten, Wim
- New England Journal of Medicine, Vol. 361, Issue 13
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia: Resistance to Cytarabine in AML
journal, June 2002
- Galmarini, Carlos M.; Thomas, Xavier; Calvo, Fabien
- British Journal of Haematology, Vol. 117, Issue 4
An update of current treatments for adult acute myeloid leukemia
journal, January 2016
- Dombret, Hervé; Gardin, Claude
- Blood, Vol. 127, Issue 1
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
journal, September 1983
- Slevin, M. L.; Piall, E. M.; Aherne, G. W.
- Journal of Clinical Oncology, Vol. 1, Issue 9
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
journal, October 1984
- Tewey, K.; Rowe, T.; Yang, L.
- Science, Vol. 226, Issue 4673
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study
journal, January 2018
- Swords, Ronan T.; Azzam, Diana; Al-Ali, Hassan
- Leukemia Research, Vol. 64
Selecting initial treatment of acute myeloid leukaemia in older adults
journal, March 2017
- Podoltsev, Nikolai A.; Stahl, Maximilian; Zeidan, Amer M.
- Blood Reviews, Vol. 31, Issue 2
Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma
journal, November 2001
- Hempel, Georg; Flege, Silke; Würthwein, Gudrun
- Cancer Chemotherapy and Pharmacology, Vol. 49, Issue 2
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
journal, January 2009
- Sekeres, Mikkael A.; Elson, Paul; Kalaycio, Matt E.
- Blood, Vol. 113, Issue 1
Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside
journal, June 1982
- Weinstein, Hj; Griffin, Tw; Feeney, J.
- Blood, Vol. 59, Issue 6
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
journal, April 2009
- Juliusson, Gunnar; Antunovic, Petar; Derolf, Åsa
- Blood, Vol. 113, Issue 18
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
journal, May 2013
- Roos, Wynand P.; Kaina, Bernd
- Cancer Letters, Vol. 332, Issue 2
Correlation of cytotoxicity with incorporation of ara-C into DNA.
journal, October 1980
- Kufe, D. W.; Major, P. P.; Egan, E. M.
- Journal of Biological Chemistry, Vol. 255, Issue 19
Works referencing / citing this record:
Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science
journal, May 2019
- Malfatti, Michael A.; Buchholz, Bruce A.; Enright, Heather A.
- Toxics, Vol. 7, Issue 2
Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science
journal, May 2019
- Malfatti, Michael A.; Buchholz, Bruce A.; Enright, Heather A.
- Toxics, Vol. 7, Issue 2